Nature Medicine, Article first published online: February 26, 2018
Publications and Presentations
A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189 Phosphate, a Neurogenic Compound, among Outpatients with Major Depressive Disorder
56th American College of Neuropsychopharmacology (ACNP) Annual Meeting; Palm Springs, California. Presented on Monday, December 4, 2017.
Reversal of Radiation-induced Cognitive Impairment by Oral Administration of Neurogenic Small Molecule Compound NSI-189
Radiation Research Society Annual Meeting, October 19, 2017
Annual Meeting of the Diabetic Neuropathy Study Group of the EASD (European Association for the Study of Diabetes), held in Bucharest, Romania.
Annals of Neurology, Article first published online: February 12, 2016.
A Phase 1B, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation Study of NSI-189 Phosphate, a Neurogenic Compound, in Depressed Patients
Molecular Psychiatry, Article first published online: December 8, 2015.
International Society for Stem Cell Research (ISSCR) Annual Meeting, Stockholm, Sweden, Poster presented June 25, 2015.
Biomarker Profiling of NSI-189 Phosphate, a Neurogenic Compound, in Patients with Major Depressive Disorder (MDD) during a Phase Ib Randomized Double-Blind, Placebo-Controlled Trial
CNS Summit, Poster presented November 14, 2014.
Annals of Clinical and Translational Neurology, Article first published online: October 22, 2014.
Effects of NSI-189, a neurogenic compound, on quantitative electroencephalography (qEEG) in patients with major depressive disorder (MDD) during a phase 1b randomized, double-blind, placebo controlled, multiple ascending dose study
The International College of Neuropsychopharmacology (CINP), Abstract posted June 17, 2014, in advance of presentation at 29th CINP World Congress of Neuropsychopharmacology: June 24, 2014.